Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon...
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
...
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
- Associated Therapies
- -
Celecoxib in Treating Patients With Precancerous Lesions of the Mouth
- Conditions
- First Posted Date
- 2004-01-07
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00014404
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Weill Medical College of Cornell University, New York, New York, United States
Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00073866
- Locations
- 🇺🇸
Silver Cross Hospital, Joliet, Illinois, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸Evanston Northwestern Health Care - Evanston Hospital, Evanston, Illinois, United States
Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy
- Conditions
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2012-05-23
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT00073970
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00072072
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove Polyps
- First Posted Date
- 2003-11-05
- Last Posted Date
- 2013-04-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1170
- Registration Number
- NCT00005094
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix
- Conditions
- First Posted Date
- 2003-11-05
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00072540
Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- Locations
- 🇫🇷
Hopital Tenon, Paris, France
Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2003-10-21
- Last Posted Date
- 2013-04-29
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT00030420
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2016-12-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 75
- Registration Number
- NCT00070057
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 140
- Registration Number
- NCT00070486
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Columbia (Truman Memorial), Columbia, Missouri, United States
🇺🇸Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri, United States
🇺🇸CCOP - North Shore University Hospital, Manhasset, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.